ALX Oncology Holdings Inc Ordinary Shares ALXO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.30
- Day Range
- $1.21–1.38
- 52-Week Range
- $1.05–2.66
- Bid/Ask
- $1.19 / $1.28
- Shares Outstanding
- 138.28M
- Market Cap
- $168.70M
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 48
- Website
- https://www.alxoncology.com
Valuation
|
Metric
|
ALXO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALXO
|
|---|---|
Quick Ratio | 9.43 |
Current Ratio | 9.71 |
Interest Coverage | −59.38 |
Quick Ratio
ALXO
Profitability
|
Metric
|
ALXO
|
|---|---|
Return on Assets (Normalized) | −60.12% |
Return on Equity (Normalized) | −81.94% |
Return on Invested Capital (Normalized) | −76.39% |
Return on Assets
ALXO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|m<!jjM | LOCK|!<Cg | $128B | |||
| Moderna Inc
MRNA
| LOCK|<xMVc#x | LOCK|?$? | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&@#Qh^x | LOCK|bg$Bk | $76B | |||
| argenx SE ADR
ARGX
| LOCK|hK^Q@% | LOCK|P! | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@dR#m> | LOCK|rv | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ZbXNtg | LOCK|Lv$&# | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?@V<&&# | LOCK|yYL>l | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|tKlbqx | LOCK|f&c | $24B | |||
| Incyte Corp
INCY
| LOCK|x$jkq> | LOCK|MCB | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|rqKt>C | LOCK|TVf | $15B |
United States